HSPA9 and invasive ductal breast carcinoma: A total of 155 invasive ductal carcinomas of breast patients with strict follow-up, 52 ductal carcinomas in situ (DCIS) and 45 adjacent non-tumor breast tissues were selected for immunohistochemical staining of mortalin protein.